These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 2562178

  • 1. Forward and reverse changes in Ig/myc translocation carrying tumors.
    Klein G.
    Princess Takamatsu Symp; 1989; 20():135-42. PubMed ID: 2562178
    [Abstract] [Full Text] [Related]

  • 2. Immunological aspects of B-cell derived tumors in humans and rodents.
    Klein G.
    Princess Takamatsu Symp; 1988; 19():3-13. PubMed ID: 2855874
    [Abstract] [Full Text] [Related]

  • 3. EBV-B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review).
    Klein G.
    Acta Microbiol Immunol Hung; 1996; 43(2-3):97-105. PubMed ID: 8876725
    [Abstract] [Full Text] [Related]

  • 4. Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line.
    Klein G.
    Ciba Found Symp; 1989; 142():36-48; discussion 48-53. PubMed ID: 2545422
    [Abstract] [Full Text] [Related]

  • 5. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors.
    Klein G.
    AIDS Res; 1986 Dec; 2 Suppl 1():S167-76. PubMed ID: 3030345
    [Abstract] [Full Text] [Related]

  • 6. c-MYC impairs immunogenicity of human B cells.
    Schlee M, Schuhmacher M, Hölzel M, Laux G, Bornkamm GW.
    Adv Cancer Res; 2007 Dec; 97():167-88. PubMed ID: 17419945
    [Abstract] [Full Text] [Related]

  • 7. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
    Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC, Janz S.
    Cancer Res; 2005 Feb 15; 65(4):1306-15. PubMed ID: 15735016
    [Abstract] [Full Text] [Related]

  • 8. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
    Jochner N, Eick D, Zimber-Strobl U, Pawlita M, Bornkamm GW, Kempkes B.
    EMBO J; 1996 Jan 15; 15(2):375-82. PubMed ID: 8617212
    [Abstract] [Full Text] [Related]

  • 9. Epstein-Barr virus and Burkitt's lymphoma.
    Magrath I, Jain V, Bhatia K.
    Semin Cancer Biol; 1992 Oct 15; 3(5):285-95. PubMed ID: 1335792
    [Abstract] [Full Text] [Related]

  • 10. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
    Ramqvist T, Magnusson KP, Wang Y, Szekely L, Klein G, Wiman KG.
    Oncogene; 1993 Jun 15; 8(6):1495-500. PubMed ID: 8502475
    [Abstract] [Full Text] [Related]

  • 11. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT, Neckers LM, Schneller HE, Woodruff LS, Magrath IT.
    Cancer Res; 1993 Jan 01; 53(1):127-32. PubMed ID: 8416737
    [Abstract] [Full Text] [Related]

  • 12. Conditioned tumorigenicity of activated oncogenes.
    Klein G, Klein E.
    Cancer Res; 1986 Jul 01; 46(7):3211-24. PubMed ID: 3011242
    [Abstract] [Full Text] [Related]

  • 13. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
    Jox A, Taquia E, Vockerodt M, Draube A, Pawlita M, Möller P, Bullerdiek J, Diehl V, Wolf J.
    Cancer Res; 1998 Nov 01; 58(21):4930-9. PubMed ID: 9810002
    [Abstract] [Full Text] [Related]

  • 14. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
    Wolf J, Pawlita M, Bullerdiek J, zur Hausen H.
    Cancer Res; 1990 May 15; 50(10):3095-100. PubMed ID: 2159373
    [Abstract] [Full Text] [Related]

  • 15. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE, Lieberman R, Sandlund J, Kiwanuka J, Novikovs L, Kirsch I, Hollis G, Magrath IT.
    Cancer Res; 1989 Jun 15; 49(12):3235-41. PubMed ID: 2497974
    [Abstract] [Full Text] [Related]

  • 16. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
    Staege MS, Lee SP, Frisan T, Mautner J, Scholz S, Pajic A, Rickinson AB, Masucci MG, Polack A, Bornkamm GW.
    Proc Natl Acad Sci U S A; 2002 Apr 02; 99(7):4550-5. PubMed ID: 11917131
    [Abstract] [Full Text] [Related]

  • 17. Chromosomal translocations in B-cell derived tumors.
    Klein G.
    Princess Takamatsu Symp; 1986 Apr 02; 17():159-70. PubMed ID: 3332008
    [Abstract] [Full Text] [Related]

  • 18. Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines.
    Masucci MG, Klein E.
    Semin Cancer Biol; 1991 Feb 02; 2(1):63-71. PubMed ID: 1655115
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
    Kelly G, Bell A, Rickinson A.
    Nat Med; 2002 Oct 02; 8(10):1098-104. PubMed ID: 12219084
    [Abstract] [Full Text] [Related]

  • 20. A potential role for antigen selection in the clonal evolution of Burkitt's lymphoma.
    Jain R, Roncella S, Hashimoto S, Carbone A, Francia di Celle P, Foa R, Ferrarini M, Chiorazzi N.
    J Immunol; 1994 Jul 01; 153(1):45-52. PubMed ID: 8207254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.